Expression of Potential Biomarker Targets by Immunohistochemistry in Cervical Carcinomas

Lulu Sun, Molly C. Schroeder, Ian S. Hagemann, John D. Pfeifer, Julie Schwarz, Perry W. Grigsby, Stephanie Markovina, Alexander Lin

Research output: Contribution to journalArticlepeer-review

Abstract

There have been few clinically useful targetable biomarkers in uterine cervical carcinomas. Estrogen receptor (ER), HER2, and fibroblast activation protein (FAP) are potential therapeutic or theranostic targets in other gynecologic and genitourinary carcinoma types. We determined the immunohistochemical expression patterns of these markers in treatment-naive cervical carcinoma, and whether expression correlated with clinical outcomes after definitive chemoradiation therapy. Tissue microarrays were created from 71 patient samples taken before therapy (57 squamous cell carcinomas and 14 nonsquamous cell carcinomas) and stained for ER, HER2, and FAP. ER was positive in 25/70 cases (36%). Of 66 tumors with evaluable HER2 staining, only 1 had positive (3+) staining (3%, positive for HER2 amplification by fluorescence in situ hybridization), and 1 had equivocal (2+) staining (negative for amplification by fluorescence in situ hybridization). The remainder were negative for HER2 overexpression. FAP expression was widely variably in the tumor stroma. ER positivity and FAP expression did not correlate with cervical recurrence, pelvic recurrence, distant recurrence, or cancer death. In conclusion, HER2 amplification is very rare in nonmetastatic treatment-naive cervical carcinomas, but if present, could represent a target for antibody therapy. ER and FAP were expressed in a subset of tumors, but expression did not correlate with clinical outcomes. These immunohistochemical markers do not demonstrate prognostic significance in treatment-naive cervical cancer, but they may have utility in targeted therapy or imaging.

Original languageEnglish
JournalInternational Journal of Gynecological Pathology
DOIs
StateAccepted/In press - 2022

Keywords

  • Cervical cancer
  • Estrogen receptor
  • Fibroblast activation protein
  • HER2
  • Immunohistochemistry

Fingerprint

Dive into the research topics of 'Expression of Potential Biomarker Targets by Immunohistochemistry in Cervical Carcinomas'. Together they form a unique fingerprint.

Cite this